Clinical Trial

Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 25, 2025 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
The study involves the use of reagents or materials for diagnostic assessments that are not commercially available, specifically a metabolomic signature for screening endometrial carcinoma and/or other types of cancers, and follows a case-control design. This study aims to achieve several objectives that contribute to evaluating the diagnostic potential of a specific "metabolomic signature" to be used for screening endometrial carcinoma. Specifically, the study seeks to assess the signature's discriminative ability in differentiating between benign endometrial neoplasms and neoplasms of different histological origins.
Trial Details
NCT Number NCT06893861
Lead Sponsor National Cancer Institute, Naples
Conditions Endometrial Carcinoma (EC)
Enrollment 3,100 participants
Start Date 2023-07-06
Primary Completion 2025-07 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2025-03-25